A population-based clinical trial comparing endocervical high-risk HPV testing using Hybrid Capture 2 and Cervista from the shenccast II study

American Journal of Clinical Pathology

Volumn 135, Issue 5, 2011, Pages 790-795

  Belinson, Jerome L ^a,d,e   Wu, Ruifang ^b   Belinson, Suzanne E ^a   Qu, Xinfeng ^c   Yang, Bin ^d   Du, Hui ^b   Wu, Ruosong ^c   Wang, Chun ^b   Zhang, Lijie ^b   Zhou, Yanqiu ^b   Liu, Ying ^b   Pretorius, Robert G ^e  

^a Preventive Oncology International   (United States)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^c Royal Ladies Clinic   (China)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Kaiser Permanente ^*  (United States)

Author keywords

Cervical Cancer Screening; Cervista; HPV; Human papillomavirus; Hybrid Capture 2

Indexed keywords

ADULT; ANALYZER; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CHINA; CLINICAL TRIAL; COLPOSCOPY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 79954997154     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPKA6ATAPBZ6JQ     Document Type: Article

References (16)

1. Cuzick J, Clavel C, Petry KU, et al. European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101. (Pubitemid 44116919)
2. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical intraepithelial neoplasia. Gynecol Oncol. 2001;83:439-444. (Pubitemid 33033096)
3. Shi JF, Belinson JL, Zhao FH, et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. Am J Epidemiol. 2009;170:708-716.
4. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337: a1754. doi:10.1136/bmj.a1754.
5. Cervista HPV HR and Genfind DNA Extraction Kit: P080014. US Food and Drug Administration Web site. http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm134056.htm. Updated June 29, 2009. Accessed February 2010.
6. Digene Hybrid Capture 2 High-Risk HPV DNA Test: P890064 S009 A004. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm082556.htm. Updated June 29, 2009. Accessed February 2010.
7. Day SP, Hudson A, Mast A, et al. Analytical performance of the Investigational use Only Cervista HPV HR test as determined by a multi-center study. J Clin Virol. 2009;45(suppl 1): S63-S72.
8. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999;80:1306-1311. (Pubitemid 29308597)
9. Einstein MH, Martens MG, Garcia FA, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol. 2010;118:116-122.
10. Kinney W, Stoler MH, Castle PE. Patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134:193-199.
11. Söderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2008;54:86-92. (Pubitemid 351182600)
12. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890. (Pubitemid 38657490)
13. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer. 1999;81:554-558. (Pubitemid 29458814)
14. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province Cervical Cancer Screening Study II: self-sampling for highrisk human papillomavirus compared to direct sampling for HPV and liquid based cervical cytology. Int J Gynecol Cancer. 2003;13:819-826. (Pubitemid 38235227)
15. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632. (Pubitemid 46986496)
16. Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20:1705-1713.